Old Web
English
Sign In
Acemap
>
authorDetail
>
Paul Knöbl
Paul Knöbl
University of Vienna
Medicine
Internal medicine
Immunology
Caplacizumab
Adverse effect
4
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study
2018
Blood
Johanna A. Kremer Hovinga
Marie Scully
Spero R. Cataland
Flora Peyvandi
Paul Coppo
Paul Knöbl
Javier de la Rubia
Katerina Pavenski
Jessica Minkue
Rui de Passos Sousa
Filip Callewaert
Hilde De Winter
Ara Metjian
Show All
Source
Cite
Save
Citations (4)
Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study
2018
Blood
Spero R. Cataland
Marie Scully
Flora Peyvandi
Paul Coppo
Paul Knöbl
Johanna A. Kremer Hovinga
Ara Metjian
Javier de la Rubia
Katerina Pavenski
Jessica Minkue
Rui de Passos Sousa
Filip Callewaert
Hilde De Winter
Show All
Source
Cite
Save
Citations (4)
Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study
2017
Blood
Katharina Holstein
Andrea Smith
Paul Knöbl
Christiane Dobbelstein
Wolfgang Miesbach
Michael Spannagl
Jürgen Heinz
Ute Scholz
Hermann Eichler
Angela Huth-Kühne
Robert Klamroth
Armin Koch
Andreas Tiede
Show All
Source
Cite
Save
Citations (1)
Treatment of adults with sepsis-induced coagulopathy and purpura fulminans with a plasma-derived protein C concentrate (Ceprotin) ®
2003
Critical Care
Peter Schellongowski
Edith Bauer
Gottfried J. Locker
Michael Frass
Thomas Staudinger
Paul Knöbl
Show All
Source
Cite
Save
Citations (1)
1